Is risky pediatric research without prospect of direct benefit ever justified?

American Journal of Bioethics

Volumn 7, Issue 3, 2007, Pages 12-15

  Martin, Rebecca A ^a   Robert, Jason Scott ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CHILD; CLINICAL TRIAL; EMBRYONIC STEM CELL; ETHICS; HUMAN; HUMAN EXPERIMENT; JUVENILE; NERVE CELL; NEURONAL CEROID LIPOFUSCINOSIS; NOTE; PROFESSIONAL STANDARD; RESEARCH SUBJECT; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TRANSPLANTATION; UNITED STATES; VULNERABLE POPULATION;

BRAIN; CHILD; CLINICAL TRIALS; EMBRYONIC STEM CELLS; ETHICS COMMITTEES, RESEARCH; HUMAN EXPERIMENTATION; HUMANS; MINORS; NEURONAL CEROID-LIPOFUSCINOSES; NEURONS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; RESEARCH SUBJECTS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; THERAPEUTIC HUMAN EXPERIMENTATION; UNITED STATES; VULNERABLE POPULATIONS;

EID: 33947244966     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160601171606     Document Type: Note

References (12)

1. Associated Press. 2005. FDA approves first brain stem cell transplant. Available at http://www.msnbc.msn.com/id/ 9767034/page/2/ (accessed December 21, 2006).
2. Arkin, L. M., D. Sondhi, S. Worgall, et al. 2005. Confronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders. Human Gene Therapy 16(9): 1028- 1036.
3. Fisher, C. B., S. Z. Kornetsky, and E. D. Prentice. 2007. Determining risk in pediatric research with no prospect of direct benefit: Time for a national consensus on the interpretation of federal regulations. The American Journal of Bioethics 7(3): 5-10.
4. Kimmelman, J., F. Baylis, and K. Glass. 2006. Stem cell trials: Lessons from gene transfer research. Hastings Center Report 36(1): 23- 26.
5. Harrison, C., N. P. Kenny, M. Sidarous, and M. Rowell. 1997. Bioethics for clinicians 9: Involving children in medical decisions. Canadian Medical Association Journal 156(6): 825-828.
6. Oberman, M., and J. Frader. 2003. Dying children and clinical research: Access to clinical trials as burden and benefit. American Journal of Law and Medicine 29(2-3): 301-317.
7. Robert, J. S. 2004. Model systems in stem cell research. BioEssays 26(9): 1005-1012.
8. Robert, J. S., J. Maienschein, and M. D. Laubichler. 2006. Systems bioethics and stem cell research. Journal of Bioethical Inquiry 3(1-2): 19-31.
9. StemCells, Inc. 2005. StemCells, Inc. receives clearance to initiate Phase I clinical trial of neural stem cells to treat Batten disease. Press release, 20 October. Available at http://www. stemcellsinc.com/news/051020. html (accessed December 21, 2006).
10. StemCells, Inc. 2006a. StemCells, Inc. receives IRB approval from Oregon Health & Science University to begin Phase I clinical trial in Batten disease. Press release, 9 March. Available at http://www. stemcellsinc.com/news/060309.html (accessed December 21, 2006).
11. StemCells, Inc. 2006b. StemCells, Inc. announces first human neural stem cell transplant. Press release, 15 November. Available at http:// www.stemcellsinc.com/news/061115.html (accessed December 21, 2006).
12. Taupin, P. 2006. HuCNS-SC (StemCells). Current Opinion in Molecular Therapeutics. 8(2): 156-163.